Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study

Overview of attention for article published in Frontiers in immunology, March 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 6 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 33,847 followers.

RT @FrontImmunol: New Research: Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-bas…

29 Mar 2024

Reply Repost Favourite

New Research: Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study: Background BVAC-C, a B cell– and monocyte-based immunotherapeutic vaccine… https://t.co/peNwo7Dd

29 Mar 2024

Reply Repost Favourite

Efficacy and safety of BVAC-C in HPV type 16- or 18–positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study https://t.co/FHIiyCCmdb #FrontImmunol

28 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.